FcγR Binding and ADCC Activity of Human IgG Allotypes.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 17 01 2020
accepted: 01 04 2020
entrez: 22 5 2020
pubmed: 22 5 2020
medline: 18 3 2021
Statut: epublish

Résumé

Antibody dependent cellular cytotoxicity (ADCC) is an Fc-dependent effector function of IgG important for anti-viral immunity and anti-tumor therapies. NK-cell mediated ADCC is mainly triggered by IgG-subclasses IgG1 and IgG3 through the IgG-Fc-receptor (FcγR) IIIa. Polymorphisms in the immunoglobulin gamma heavy chain gene likely form a layer of variation in the strength of the ADCC-response, but this has never been studied in detail. We produced all 27 known IgG allotypes and assessed FcγRIIIa binding and ADCC activity. While all IgG1, IgG2, and IgG4 allotypes behaved similarly within subclass, large allotype-specific variation was found for IgG3. ADCC capacity was affected by residues 291, 292, and 296 in the CH2 domain through altered affinity or avidity for FcγRIIIa. Furthermore, allotypic variation in hinge length affected ADCC, likely through altered proximity at the immunological synapse. Thus, these functional differences between IgG allotypes have important implications for therapeutic applications and susceptibility to infectious-, allo- or auto-immune diseases.

Identifiants

pubmed: 32435243
doi: 10.3389/fimmu.2020.00740
pmc: PMC7218058
doi:

Substances chimiques

FCGR3A protein, human 0
Immunoglobulin Allotypes 0
Immunoglobulin G 0
Immunoglobulin Heavy Chains 0
Receptors, IgG 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

740

Informations de copyright

Copyright © 2020 de Taeye, Bentlage, Mebius, Meesters, Lissenberg-Thunnissen, Falck, Sénard, Salehi, Wuhrer, Schuurman, Labrijn, Rispens and Vidarsson.

Références

Transfusion. 2014 Mar;54(3):665-71
pubmed: 23829325
J Immunol. 1993 Sep 1;151(5):2529-37
pubmed: 8360475
Oncoimmunology. 2014 Jan 1;3(1):e27317
pubmed: 24701371
J Immunol. 2017 May 15;198(10):3999-4011
pubmed: 28404636
Int Arch Allergy Immunol. 1998 Mar;115(3):215-9
pubmed: 9531163
Arthritis Rheum. 2008 Oct;58(10):3239-46
pubmed: 18821675
Methods Mol Biol. 2017;1503:31-47
pubmed: 27743357
Immunol Cell Biol. 2019 Jul;97(6):526-537
pubmed: 30680791
Exp Clin Immunogenet. 1989;6(1):7-17
pubmed: 2698222
J Biol Chem. 2014 Feb 28;289(9):6098-109
pubmed: 24425871
Methods Mol Biol. 2012;882:635-80
pubmed: 22665258
Clin Cancer Res. 2007 Mar 15;13(6):1875-82
pubmed: 17363544
Blood. 1983 Oct;62(4):873-82
pubmed: 6349718
J Immunol. 2017 Jul 1;199(1):204-211
pubmed: 28566370
MAbs. 2015;7(4):662-71
pubmed: 25962087
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12669-74
pubmed: 21768335
J Immunol Methods. 2005 Nov 30;306(1-2):151-60
pubmed: 16219319
ACS Chem Biol. 2018 Aug 17;13(8):2179-2189
pubmed: 30016589
Curr Opin Virol. 2017 Feb;22:89-96
pubmed: 28088123
Antibodies (Basel). 2019 Apr 25;8(2):
pubmed: 31544836
Mol Immunol. 2016 May;73:69-75
pubmed: 27058641
J Proteome Res. 2016 Jul 1;15(7):2198-210
pubmed: 27267458
Hum Immunol. 1998 Nov;59(11):720-7
pubmed: 9796740
PLoS Pathog. 2019 Dec 16;15(12):e1008064
pubmed: 31841557
PLoS One. 2015 Aug 12;10(8):e0134949
pubmed: 26266936
Nat Genet. 2017 Aug;49(8):1182-1191
pubmed: 28628107
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Front Immunol. 2015 Jul 27;6:368
pubmed: 26284063
J Immunol. 2014 Aug 1;193(3):1071-9
pubmed: 24965774
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Infect Dis. 2012 Apr 1;205(7):1147-54
pubmed: 22389226
Front Immunol. 2017 Aug 02;8:877
pubmed: 28824618
Scand J Immunol. 1990 Nov;32(5):517-28
pubmed: 2125362
PLoS One. 2015 Oct 07;10(10):e0140120
pubmed: 26444434
PLoS Med. 2017 Oct 9;14(10):e1002403
pubmed: 28991911
Arthritis Res Ther. 2010;12(6):R221
pubmed: 21187010
Clin Immunol. 2013 Dec;149(3):475-86
pubmed: 24239836
Nat Commun. 2011 Dec 20;2:599
pubmed: 22186895
MAbs. 2019 Oct;11(7):1191-1196
pubmed: 31276431
Sci Transl Med. 2014 Mar 19;6(228):228ra39
pubmed: 24648342
Trends Immunol. 2019 Mar;40(3):197-211
pubmed: 30745265
Sci Rep. 2019 Jul 10;9(1):9995
pubmed: 31292524
J Virol. 2013 Jul;87(13):7550-7
pubmed: 23637394
Mol Immunol. 2018 Feb;94:54-60
pubmed: 29268168
Front Immunol. 2017 Dec 20;8:1883
pubmed: 29326728
Am J Phys Anthropol. 2004 Oct;125(2):175-92
pubmed: 15365983
Science. 2005 Dec 2;310(5753):1510-2
pubmed: 16322460
Eur J Immunogenet. 1998 Oct;25(5):349-55
pubmed: 9805657
J Immunol. 2019 Dec 15;203(12):3126-3135
pubmed: 31748349
Nat Rev Immunol. 2002 Oct;2(10):735-47
pubmed: 12360212
MAbs. 2018 Jul;10(5):693-711
pubmed: 29733746
J Exp Med. 1987 Nov 1;166(5):1351-61
pubmed: 3500259
Mol Immunol. 2005 Feb;42(4):501-10
pubmed: 15607806
Immunol Res. 2008;40(2):179-91
pubmed: 18213529
Anal Biochem. 2013 Aug 1;439(1):4-6
pubmed: 23583822
PLoS Med. 2007 Nov 13;4(11):e320
pubmed: 18001147
Blood. 2004 Sep 15;104(6):1793-800
pubmed: 15172969
Transfusion. 2019 Feb;59(2):754-761
pubmed: 30488958
Pharmacogenet Genomics. 2009 May;19(5):383-7
pubmed: 19319024
Mol Immunol. 1992 Mar;29(3):319-26
pubmed: 1557042
Science. 2006 Aug 4;313(5787):670-3
pubmed: 16888140
MAbs. 2009 Jul-Aug;1(4):332-8
pubmed: 20073133
J Virol. 1994 Aug;68(8):4821-8
pubmed: 7518527
Cell. 2018 Jun 28;174(1):131-142.e13
pubmed: 29958103
Front Immunol. 2018 Aug 02;9:1788
pubmed: 30116249
Clin Vaccine Immunol. 2016 Aug 05;23(8):698-706
pubmed: 27307451
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Hum Immunol. 2008 Mar;69(3):158-64
pubmed: 18396207
Eur J Hum Genet. 2001 Oct;9(10):765-72
pubmed: 11781688
Sci Transl Med. 2014 Mar 19;6(228):228ra38
pubmed: 24648341
Front Immunol. 2019 Mar 22;10:548
pubmed: 30967872
Cancer Res. 2008 May 15;68(10):3863-72
pubmed: 18483271
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
J Immunol. 2016 Jan 15;196(2):607-13
pubmed: 26685205

Auteurs

Steven W de Taeye (SW)

Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Arthur E H Bentlage (AEH)

Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Mirjam M Mebius (MM)

Genmab, Utrecht, Netherlands.

Joyce I Meesters (JI)

Genmab, Utrecht, Netherlands.

Suzanne Lissenberg-Thunnissen (S)

Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

David Falck (D)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.

Thomas Sénard (T)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.

Nima Salehi (N)

Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Manfred Wuhrer (M)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.

Janine Schuurman (J)

Genmab, Utrecht, Netherlands.

Aran F Labrijn (AF)

Genmab, Utrecht, Netherlands.

Theo Rispens (T)

Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Gestur Vidarsson (G)

Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH